{"filing":{"accession_number":"0001193125-26-389785","cik":"0000728387","ticker":"CATX","company_name":"Perspective Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-14","report_date":"2026-09-14","primary_document":"catx-20260914.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/728387/000119312526389785/catx-20260914.htm"},"events":[{"id":33076,"run_id":30402,"accession_number":"0001193125-26-389785","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Perspective Therapeutics announced a clinical collaboration and supply agreement with Merck to evaluate [212Pb]PSV359 in combination with Keytruda® in FAP-α positive solid tumors. This is a material strategic partnership involving a Phase 1/2a clinical trial amendment with a major pharmaceutical company providing drug supply at no cost. While this is clearly an operational/strategic business event, it does not fit the specific categories of M\u0026A activity, debt issuance, or other named financial/legal events. The collaboration represents a significant clinical development milestone and partnership that would affect investor assessment of the company's pipeline and commercial prospects.","company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","filing_date":"2026-09-14","form":"8-K","submitted_at":null,"items":[{"id":36414,"accession_number":"0001193125-26-389785","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Perspective Therapeutics announced a clinical collaboration and supply agreement with Merck to evaluate [212Pb]PSV359 in combination with Keytruda® in FAP-α positive solid tumors. This is a material strategic partnership involving a Phase 1/2a clinical trial amendment with a major pharmaceutical company providing drug supply at no cost. While this is clearly an operational/strategic business event, it does not fit the specific categories of M\u0026A activity, debt issuance, or other named financial/legal events. The collaboration represents a significant clinical development milestone and partnership that would affect investor assessment of the company's pipeline and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T10:21:38.360874+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36414,"accession_number":"0001193125-26-389785","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Perspective Therapeutics announced a clinical collaboration and supply agreement with Merck to evaluate [212Pb]PSV359 in combination with Keytruda® in FAP-α positive solid tumors. This is a material strategic partnership involving a Phase 1/2a clinical trial amendment with a major pharmaceutical company providing drug supply at no cost. While this is clearly an operational/strategic business event, it does not fit the specific categories of M\u0026A activity, debt issuance, or other named financial/legal events. The collaboration represents a significant clinical development milestone and partnership that would affect investor assessment of the company's pipeline and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T10:21:38.360874+00:00","company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","filing_date":"2026-09-14"}]}